Update on stents: Recent studies on the TAXUS^® stent system in small vessels

(2194) Views  (413) Full article downloads

Authors: Shuzou Tanimoto, Joost Daemen, Patrick W Serruys

Published Date October 2007 Volume 2007:3(4) Pages 481 - 490

DOI: http://dx.doi.org/10.2147/VHRM.S

Shuzou Tanimoto, Joost Daemen, Patrick W Serruys

Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands

Abstract: Small vessel size (<3 mm) has been identified as an independent predictive factor of restenosis after percutaneous coronary intervention when using bare metal stents (BMS). It remains controversial whether BMS placement in small vessels has an advantage over balloon angioplasty in terms of angiographic and clinical outcomes. The advent of drug eluting stents (DES), either paclitaxel-eluting stents (PES) or sirolimus-eluting stents (SES), has strongly impacted interventional cardiology by significantly reducing restenosis and the need for repeat revascularization. Therefore, it was also expected that DES could substantially reduce restenosis in smaller vessels. However, even in the DES era, small vessel size remains an independent predictor of angiographic and clinical restenosis. To date, only a few studies systematically investigate the clinical effect of DES placement in small vessels. In addition, some potential issues with the use of DES have been raised, such as late stent thrombosis and late restenosis. In order to (i) establish the superiority of DES over BMS; (ii) verify the efficacy and safety of DES; and (iii) critically assess the superiority of one DES over the other in patients with small coronary arteries, further multicenter, randomized clinical trials with larger sample size are warranted.

Keywords: paclitaxel, stent, coronary artery disease, restenosis

Readers of this article also read: